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Background. Australian Indigenous children are the only population worldwide to receive the 7-valent pneu-
mococcal conjugate vaccine (7vPCV) at 2, 4, and 6 months of age and the 23-valent pneumococcal polysaccharide
vaccine (23vPPV) at 18 months of age. We evaluated this program’s effectiveness in reducing the risk of hospi-
talization for acute lower respiratory tract infection (ALRI) in Northern Territory (NT) Indigenous children aged
5–23 months.
Methods. We conducted a retrospective cohort study involving all NT Indigenous children born from 1 April
2000 through 31 October 2004. Person-time at-risk after 0, 1, 2, and 3 doses of 7vPCV and after 0 and 1 dose
of 23vPPV and the number of ALRI following each dose were used to calculate dose-specific rates of ALRI for
children 5–23 months of age. Rates were compared using Cox proportional hazards models, with the number of
doses of each vaccine serving as time-dependent covariates.
Results. There were 5482 children and 8315 child-years at risk, with 2174 episodes of ALRI requiring hos-
pitalization (overall incidence, 261 episodes per 1000 child-years at risk). Elevated risk of ALRI requiring hospi-
talization was observed after each dose of the 7vPCV vaccine, compared with that for children who received no
doses, and an even greater elevation in risk was observed after each dose of the 23vPPV (adjusted hazard ratio
[HR] vs no dose, 1.39; 95% confidence interval [CI], 1.12–1.71; ). Risk was highest among childrenPp .002
vaccinated with the 23vPPV who had received !3 doses of the 7vPCV (adjusted HR, 1.81; 95% CI, 1.32–2.48).
Conclusions. Our results suggest an increased risk of ALRI requiring hospitalization after pneumococcal vac-
cination, particularly after receipt of the 23vPPV booster. The use of the 23vPPV booster should be reevaluated.
Acute lower respiratory tract infections (ALRI) are the
leading cause of hospitalization and preventable death
among Australian Indigenous children in the Northern
Territory (NT) [1]. Repeated ALRI requiring hospital-
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ization predisposes Indigenous children to a higher risk
of bronchiectasis and chronic lung disease [2].
Beginning in June 2001, Indigenous infants in Aus-
tralia were among the first in the world to routinely
receive pneumococcal vaccines (Table 1), including a
catch-up program. By December 2001, 170% of eligible
children had received at least 1 dose of the 7vPCV [3].
The provision of 23vPPV at 18 months of age was
intended to provide boosting for 7vPCV serotypes and
extended coverage to non-7vPCV serotypes in a pop-
ulation at high risk for infection. In this study, we ex-
amined the effectiveness of the 3 plus 1 (3 doses of
7vPCV plus 1 dose of 23vPPV) immunization program
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Table 1. Pneumococcal Immunization Schedule for Australian Indigenous Children
Age at time of first vaccination 7vPCV schedule 23vPPV booster
2–6 Months 3 doses administered 2 months apart 18 months of age
7–17 Months 2 doses administered 2 months apart 18 months of age or 2 months after primary dose,
whichever is later
18–23 Months 1 dose 2 months after primary dose
24–59 Months (Central Australia only) 1 dose 2 months after primary dose
NOTE. 7vPCV, 7-valent pneumococcal conjugate vaccine; 23vPPV, 23-valent pneumococcal polysaccharide vaccine.
at a population level. We aimed to determine whether the pro-
gram reduced the risk of ALRI requiring hospitalization among
NT Indigenous children aged 5–23 months of age.
METHODS
Design overview. This was a retrospective cohort study de-
rived from a larger study of all NT resident Indigenous infants
born from 1 April 1997 through 28 February 2005 [4]. In the
current study, only children born from 1 April 2000 through
31 October 2004 (those eligible for primary or catch-up pneu-
mococcal immunization from 1 June 2001) were eligible for
inclusion. We compared the hazard for ALRI requiring hos-
pitalization according to the number of 7vPCV and 23vPPV
vaccination doses received.
The Human Research Ethics Committee of the NT Depart-
ment of Health and Community Services and the Menzies
School of Health Research provided approval (approval ID #05/
49).
Setting. There are ∼1500 Indigenous births per year in the
NT; 195% occur in 1 of 5 public hospitals [5]. Health care
across the NT is highly accessible, with remote Indigenous in-
fants presenting to primary health centers an average of every
2 weeks in the first year of life [6].
Study participants. Children eligible for study inclusion
were identified using birth records in the hospital discharge
data set and augmenting these with children identified through
the NT Immunisation Register (NTIR). This was possible be-
cause all persons born in the NT or who attend any public
health service are allocated a unique health record number that
is used for hospitalizations and for NTIR entry. The NTIR is
a population-based, comprehensive immunization register that
vaccine providers report to on a regular basis. Children not
born in a public hospital are added to the NTIR through com-
pulsory registration on the NT Midwives’ Collection or at the
first immunization or health care encounter. This system allows
linkage of vaccination status and hospitalizations over time.
Mobility is predominantly limited to regions within the NT,
and interstate migration is infrequent.
Exposure data. Immunization history for all children in
the cohort, consisting of vaccination dates and vaccine type,
was obtained from the NTIR. The quality and completeness of
immunization history on the NTIR is well established, and
regular audits occur [7, 8].
Outcome data. Hospitalization data were obtained from
the NT Hospital Discharge Dataset, which captures all Indig-
enous child hospitalizations in the 5 NT public hospitals (in-
cluding children transferred interstate). The primary outcome,
ALRI requiring hospitalization, was defined as any discharge
diagnosis code J10-J22, inclusive, as defined in the International
Classification of Diseases, 10th Revision, Australian Modification
(ICD-10-AM) [9]. Secondary outcomes included hospitalized
pneumonia not coded as viral (unspecified pneumonia codes
and excluding bronchiolitis, codes J13–16, J18) and World
Health Organization (WHO)–defined radiologically confirmed
pneumonia [10]. For the latter, all chest radiographs, regardless
of indication, obtained within 3 days of hospital admission (to
exclude nosocomial pneumonia) were assessed for WHO-de-
fined radiological consolidation by blinded readers [10].
Covariates. Demographic information, vaccination and
hospitalization histories, and region of residence at birth (Top
End/Central Australia) were available.
Statistical analysis. Vaccination timing is summarized us-
ing cumulative incidence graphs. Because most children passed
through 1 vaccination states during the course of follow-up,
incidence of ALRI (and other pneumonia end points) was com-
pared, not on an individual child basis, but by allocating periods
of follow-up time to categories and comparing between these
categories, using standard methods of survival analysis. Thus,
an individual child may, at a particular age (eg, 6 months of
age), be contributing to the estimation of incidence after 2 doses
of 7vPCV, and at a later age (eg, 8 months of age) be contrib-
uting to comparisons concerning exposure to 3 doses of 7vPCV.
We included person-time from when each child turned 5
months of age, by which time infants should have received 2
7vPCV doses, until they turned 24 months of age, died, or
reached the end-date of the study (31 March 2005). Time prior
to 5 months of age was not included, because we assumed that
at least 2 7vPCV doses are required for any ALRI protection;
analyzing time prior to this point was therefore not informative.
Children who died during the study without a date of death
recorded were censored at the last vaccination or hospital ad-
mission date. A small number of children with vaccination
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Table 2. Characteristics of Children in the Analysis
Variable
No. (%)
of children
(n p 5482)
Female sex 2632 (48)
Northern Territory region of residence
Top End 3876 (71)
Center 1606 (29)
Comorbidities at !24 months of age
Episodes of anemia 1204 (22)
Episodes of malnutrition 363 (7)
Episodes of gastroenteritis 1890 (34)
7vPCV vaccination status at 24 months of age
No doses 510 (9)
1 Dose only 417 (8)
2 Doses only 955 (17)
3 Doses 3600 (66)
23vPCV booster vaccination status at 24 months of age
No dose of 23vPPV 2166 (40)
!2 Doses 7vPCV plus 23vPPV 162 (3)
2 Doses of 7vPCV plus 23vPPV 605 (11)
3 doses of 7vPCV plus 23vPPV 2549 (46)
No. of episodes of ALRI at !24 months of age
0 Episodes 3794 (69)
1 Episode 1001 (18)
2 Episodes 366 (7)
3 episodes 321 (6)
No. of hospital admissions for ALRI at !5 months of age
0 4811 (88)
1 531 (10)
2 115 (2)
3 25 (0)
No. of other hospital admissions at !5 months of age
0 4666 (85)
1 684 (12)
2 96 (2)
3 36 (1)
NOTE. 7vPCV, 7-valent pneumococcal conjugate vaccine; 23vPPV, 23-
valent pneumococcal polysaccharide vaccine; ALRI, acute lower respi-
ratory tract infection.
histories outside standard practice (7vPCV after 23vPPV, a sec-
ond dose of 23vPPV) were censored at the time of the later
vaccination.
Crude ALRI incidence rates were calculated separately for
follow-up time with 0, 1, 2, and 3 doses of 7vPCV and 0 and
1 dose of 23vPPV, by age group (5–8, 9–12, 13–16, 17–20, and
21–24 months of age), using the number of cases and total
time-at-risk after each dose within each age group. Incidence
rate ratios were calculated to compare rates after each dose of
7vPCV and 23vPPV with rates for those with no doses of the
respective vaccine, by age group and overall, adjusted for age
by the Mantel-Haenszel method. Model-based comparisons
were made using Cox proportional hazards regression mod-
els, again comparing ALRI risk after each dose of 7vPCV and
23vPPV with risk having received no doses of the vaccine. As
well as adjusting for age, these models allowed adjustment for
potential confounding factors that reflected the child’s risk
profile (eg, prior hospitalizations and region of residence). Mul-
tiple episodes for a child were accounted for using the con-
ditional risk set method [11], stratifying by episode number
and using robust standard errors. This method accounts for
the fact that a child is only at risk of a second episode once
they have had a first episode and that the risk of a second
episode (or subsequent episode) is different from the risk of
the first episode. The Efron method [12] was used to handle
tied survival time.
Results from the Cox models are presented as unadjusted
hazard ratios (HRs) and HRs adjusted for the child’s risk pro-
file, using the covariates sex, region of residence, and the num-
ber of ALRI and other hospital admissions prior to 5 months
of age. Additional analysis allowed for a different effect of the
23vPPV vaccine in children who had received !3 doses of
7vPCV, compared with those who received  3 doses prior to
the 23vPPV vaccination.
For all analyses, the at-risk period after each dose was defined
as commencing at 14 days after vaccine administration, allow-
ing time for an immune response to that dose. Children were
also not considered to be at risk of a new episode of ALRI and/
or pneumonia until 14 days after an episode commenced. Time-
at-risk and new hospitalizations during this 14-day refractory
period were removed from the analysis. In further analysis of
potential confounding effects, we adjusted for episodes of ane-
mia (discharge diagnosis codes: iron-deficiency anemia/ane-
mia-unspecified) or malnutrition (codes: mild/moderate/severe
protein-energy malnutrition), excluding episodes with coexist-
ing ALRI. We also assessed whether ALRI risk was different
immediately after vaccination, compared with the longer term,
by fitting a separate vaccine effect in the period within 30 days
of vaccination (including the 14 days immediately following
vaccination) and subsequently. This analysis used an additional
time-dependent covariate to categorize time since the 23vPPV
vaccination.
Finally, we assessed the potential role of bias due to differ-
ential health care utilization patterns by performing the same
Cox proportional hazards analysis for incidence of acute gas-
troenteritis requiring hospitalization (ICD-10-AM, A00-A09),
the second most common cause of hospitalization among NT
Indigenous infants [1], with no coexisting ALRI.
RESULTS
There were 5482 children included in the study (Table 2), the
timing of whose vaccinations is shown in Figure 1. In the 8315
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Figure 1. Timing of pneumococcal vaccine uptake by vaccine type and
number of doses received for Northern Territory Indigenous infants born
during the period 1 April 2000–31 October 2004. 7vPCV, 7-valent pneu-
mococcal conjugate vaccine; 23vPPV, 23-valent pneumococcal polysac-
charide vaccine.
child-years at-risk during the study period, there were 2174
episodes of ALRI that required hospitalization in 1359 children
(maximum no. of hospitalizations per child, 9), with an overall
incidence rate of 261 episodes per 1000 child-years (95% con-
fidence interval [CI], 246–278 episodes per 1000 child-years).
The incidence by age-group and age-specific and overall age-
adjusted incidence rate ratios by vaccination status are shown
in Tables 3 and 4.
Of the 2228 respiratory diagnoses attached to ALRI hos-
pitalizations, the most common were pneumonia unspeci-
fied (941 diagnoses), acute bronchiolitis (899), and unspeci-
fied ALRI (380). Specified viral pneumonias accounted for 95
diagnoses (influenza, 62; respiratory syncytial virus infection,
20), and specified bacterial pneumonias accounted for 26 di-
agnoses (pneumococcal pneumonia, 15; Haemophilus influen-
zae type b infection, 6). Sixteen infants (0.3%) died during the
study period; there were no respiratory diagnoses reported in
association with these deaths.
The crude and adjusted HRs for ALRI were elevated after
each dose of 7vPCV, compared those who had received no doses
(Table 5), with adjustment for potential confounders only
slightly reducing the apparent associations and leaving estimates
of ∼20% relative increase in risk after vaccination. An even
more striking result was seen after receipt of 23vPPV, with an
estimated 39% increased risk (95% CI, 12%–71%; ),Pp .002
compared with the risk associated with no receipt of 23vPPV
vaccine, adjusted for available confounders and history of
7vPCV vaccination. Further analysis suggested that this in-
creased risk after receipt of the 23vPPV vaccine in children was
predominantly seen in those who had received !3 doses of
7vPCV (adjusted HR, 1.81; 95% CI, 1.32–2.48) (Table 5). When
the analysis was restricted to pneumonia diagnoses only (ex-
cluding specified viral pneumonias, influenza, bronchitis, and
bronchiolitis), the same pattern of results was seen (Table 5).
Moreover, a similar pattern was seen for both ALRI and pneu-
monia when models were adjusted for anaemia and malnutri-
tion hospitalizations and when a 2003 influenza epidemic was
removed from the analysis (data not shown). There was no
interaction effect between vaccination and region of residence
( and for 7vPCV and 23vPPV, respectively; dataPp .60 Pp .81
not shown).
There were 259 episodes of chest radiograph–confirmed
pneumonia in 221 children (maximum no. of episodes per
child, 4), with an overall incidence of 31 episodes per 1000
child-years (95% CI, 27–36 episodes per 1000 child-years). Al-
though the general pattern of results (Table 5) was similar to
that for the less specific end points, there were insufficient cases
for clear interpretation of these data.
There were 1725 episodes of gastroenteritis in 1319 children
in which a coexisting diagnosis of ALRI was absent (maximum
no. of episodes per child, 5), with an overall incidence rate of
207 episodes per 1000 child-years (95% CI, 196–219 episodes
per 1000 child-years). In sharp contrast to the results for the
pneumonia end points, there was no evidence to support an
increased risk of gastroenteritis hospitalizations after any dose
of either vaccine (Table 5).
Separating the time-at-risk into !31 days and31 days after
vaccination showed a similar elevated risk of ALRI requiring
hospitalization after each dose of the 7vPCV vaccine (Table 6).
However, the increased risk of ALRI was only apparent 31
days after the 23vPPV booster (adjusted HR, 1.49; 95% CI,
1.19–1.86; ), with no evidence of increased risk im-Pp .001
mediately after vaccination (adjusted hazard rate ratio, 0.72;
95% CI, 0.49–1.08; ).Pp .11
DISCUSSION
This is, to our knowledge, the first study to report data on the
effectiveness against respiratory disease of a pneumococcal im-
munization program that combines a primary schedule of
7vPCV vaccination in infancy with a 23vPPV booster vacci-
nation in the second year of life. The study included 5482 NT
Indigenous infants 5–23 months of age in a setting of excess
respiratory and all-cause morbidity and universal capture of
ALRI requiring hospitalization. Important limitations mean
that our results should be interpreted with caution; howev-
er, the data suggest that the pneumococcal immunization pro-
gram may be unexpectedly increasing the risk of ALRI requir-
ing hospitalization among vaccinated children, especially after
the booster administration of 23vPPV.
Access to medical services is an obvious potential confounder
in this study; that is, children who present for vaccination may
also be more likely to present when unwell with ALRI. We
systematically attempted to control for and minimize this effect
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Table 3. Number of Cases, IRs, and IRRs for Acute Lower Respiratory Tract Infection (ALRI), Pneumonia, and Acute Gastroenteritis,
by Age Group and 7vPCV Vaccination Status, in Northern Territory Indigenous Infants 5–23 Months of Age
Diagnosis, age group
No. of 7vPCV doses
0 1 2 3
No. of
cases IR
No. of
cases IR IRR (95% CI)
No. of
cases IR IRR (95% CI)
No. of
cases IR IRR (95% CI)
ALRI
5–8 Months 222 370 124 382 1.03 (0.82–1.29) 250 474 1.28 (1.06–1.54) 153 4.3 1.17 (0.94–1.44)
9–12 Months 121 274 61 338 1.23 (0.89–1.69) 109 402 1.46 (1.11–1.90) 317 348 1.26 (1.02–1.57)
13–16 Months 57 180 37 234 1.30 (0.83–2.00) 49 198 1.10 (0.73–1.64) 258 241 1.33 (1.00–1.81)
17–20 Months 16 91 24 216 2.36 (1.20–4.75) 35 166 1.81 (0.98–3.51) 122 147 1.61 (0.95–2.90)
21–23 Months 7 40 17 128 3.18 (1.26–9.08) 58 199 4.94 (2.25–12.8) 137 139 3.46 (1.64–8.77)
Overalla 423 248 263 290 1.22 (1.05–1.43) 501 324 1.41 (1.23–1.61) 987 238 1.32 (1.16–1.49)
Pneumoniab
5–8 Months 83 137 49 150 1.09 (0.75–1.57) 96 180 1.31 (0.97–1.78) 52 146 1.06 (0.73–1.52)
9–12 Months 51 115 28 154 1.34 (0.81–2.16) 55 201 1.74 (1.17–2.60) 136 148 1.29 (0.93–1.81)
13–16 Months 37 117 18 113 0.97 (0.52–1.75) 27 109 0.93 (0.55–1.57) 137 127 1.09 (0.75–1.61)
17–20 Months 10 57 15 134 2.36 (0.99–5.88) 25 118 2.07 (0.96–4.84) 60 72 1.26 (0.64–2.77)
21–23 Months 3 17 8 60 3.50 (0.84–20.5) 37 127 7.35 (2.33–37.3) 72 73 4.24 (1.40–21.1)
Overalla 184 107 118 129 1.26 (1.00–1.59) 240 154 1.53 (1.26–1.86) 457 110 1.24 (1.03–1.49)
Radiologically confirmed pneumoniac
5–8 Months 35 58 17 52 0.90 (0.47–1.65) 26 49 0.84 (0.49–1.44) 20 56 0.97 (0.53–1.72)
9–12 Months 18 40 7 38 0.95 (0.33–2.38) 17 62 1.53 (0.74–3.14) 37 40 0.99 (0.55–1.85)
13–16 Months 11 35 4 25 0.73 (0.17–2.45) 9 36 1.05 (0.38–2.78) 45 42 1.21 (0.61–2.58)
17–20 Months 0 0 1 09 … 5 24 … 6 7 …
21–23 Months 0 0 0 0 … 0 0 … 1 1 …
Overalla 64 37 29 32 0.91 (0.59–1.41) 57 36 1.12 (0.79–1.61) 109 26 1.07 (0.77–1.50)
Acute gastroenteritis
5–8 Months 147 244 85 261 1.07 (0.81–1.41) 110 206 0.85 (0.66–1.09) 91 256 1.05 (0.80–1.37)
9–12 Months 119 270 38 210 0.78 (0.53–1.13) 70 256 0.95 (0.70–1.29) 258 282 1.05 (0.84–1.31)
13–16 Months 48 151 32 202 1.33 (0.82–2.12) 52 210 1.39 (0.92–2.10) 254 237 1.56 (1.14–2.17)
17–20 Months 27 154 18 162 1.05 (0.54–1.97) 51 242 1.56 (0.96–2.59) 149 179 1.16 (0.77–1.82)
21–23 Months 8 46 15 113 2.46 (0.98–6.70) 45 154 3.35 (1.56–8.24) 108 110 2.39 (1.17–5.67)
Overalla 349 204 188 207 1.06 (0.89–1.27) 328 211 1.10 (0.94–1.28) 860 207 1.20 (1.05–1.37)
NOTE. 7vPCV, 7-valent pneumococcal conjugate vaccine; CI, confidence interval; IR, incidence rate per 1000 child-years; IRR, incidence rate ratio compared
with no doses, adjusted for multiple episodes within a child.
a Incidence rate ratios adjusted for age.
b Excludes specified viral pneumonias, influenza, bronchitis and bronchiolitis.
c World Health Organization–defined end point consolidation on chest radiograph obtained within 3 days of hospital admission.
in a number of ways, by adjusting for the number of ALRIs
and other hospital admissions that occurred prior to 5 months
of age in the models and comparing ALRI risk from 17 months
of age after 23vPPV vaccination in children who had received
at least 2 or 3 doses of 7vPCV. Furthermore, we reproduced
the entire analysis using an outcome that should be unrelated
to pneumococcal vaccination status—admissions to the hos-
pital for gastroenteritis—and found no association whatsoever
between risk of hospitalization and vaccination status. None of
these analyses substantially affected the prima facie evidence of
increased risk of ALRI associated with vaccination. Although
presentation to community clinics during the first year of life
is almost universal [6], this does not translate to either timely
or complete immunization in this population [13, 14]. Op-
portunistic immunization among hospitalized children is poor
[15], and the ongoing management of children in need of fol-
low-up after hospital discharge is inadequate [16], which sug-
gests that hospitalization does not improve immunization sta-
tus. Furthermore, among hospitalized children in the NT, there
was no difference over the study period in 7vPCV vaccine cov-
erage between children with and children without comorbidities
of gastroenteritis, anemia, and/or malnutrition [4]. Given these
factors, we believe that it is unlikely that access to medical services
and differential vaccination of sicker children remain important
sources of residual confounding in our analyses.
Our findings are at odds with other, largely ecological studies
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Table 4. Number of Cases, IRs, and IRRs for Acute Lower Respiratory Tract Infection (ALRI),
Pneumonia, and Acute Gastroenteritis, by Age Group and 23vPPV Vaccination Status, in Northern
Territory Indigenous Infants 5–23 Months of Age
Diagnosis, by age group
No. of doses of 23vPPV
0 1
No. of
cases IR
No. of
cases IR IRR (95% CI)
ALRI
5–8 Months 748 415 1 377 0.91 (0.02–5.07)
9–12 Months 603 335 5 1155 3.45 (1.12–8.10)
13–16 Months 399 224 2 218 0.97 (0.12–3.54)
17–20 Months 155 142 42 176 1.24 (0.86–1.75)
21–23 Months 78 106 141 167 1.58 (1.19–2.12)
Overalla 1983 275 191 174 1.46 (1.19–1. 80)
Pneumoniab
5–8 Months 280 154 0 0 …
9–12 Months 267 147 3 681 4.63 (0.95–13.7)
13–16 Months 218 122 1 109 0.89 (0.02–5.02)
17–20 Months 90 82 20 83 1.02 (0.59–1.66)
21–23 Months 39 53 81 96 1.82 (1.23–2.74)
Overalla 894 123 105 95 1.49 (1.12–1.98)
Radiologically confirmed pneumoniac
5–8 Months 98 54 0 0 …
9–12 Months 79 43 0 0 …
13–16 Months 68 38 1 109 2.87 (0.07–16.5)
17–20 Months 11 10 1 04 0.42 (0.01–2.86)
21–23 Months 0 0 1 1 …
Overalla 256 35 3 3 0.86 (0.23–3.17)
Acute gastroenteritis, by age group
5–8 Months 432 238 1 377 1.57 (0.04–8.81)
9–12 Months 484 268 1 223 0.83 (0.02–4.67)
13–16 Months 385 216 1 109 0.51 (0.01–2.83)
17–20 Months 197 181 48 201 1.11 (0.80–1.53)
21–23 Months 82 111 94 111 1.00 (0.74–1.36)
Overalla 1580 218 145 132 1.04 (0.84–1.29)
NOTE. 23vPPV, 23-valent pneumococcal polysaccharide vaccine; CI, confidence interval; IR, incidence rate
per 1000 child-years; IRR, incidence rate ratio compared with no doses, adjusted for multiple episodes within a
child.
a Adjusted for age.
b Excludes specified viral pneumonias, influenza, bronchitis, and bronchiolitis.
c World Health Organization–defined end point consolidation on chest radiograph obtained within 3 days of
hospital admission.
that have reported decreases in all-cause pneumonia hospital-
izations of up to 39% among North American children in the
7vPCV era [17–19]. These studies had substantial differences
from our study—in particular, different vaccine schedules (4
dose schedule of 7vPCV)—whereas the NT has lower serotype
coverage of the 7vPCV [20], much higher rates of respiratory
disease [21], higher carriage rates with very early onset of col-
onization of multiple organisms [22, 23], and vastly different
socioeconomic and environmental circumstances. The Amer-
ican studies did not have direct linkage to vaccination status
and did not account for changes in risk over small intervals of
time throughout infancy (achieved by the Cox modelling ap-
proach). Three-dose coverage was less than optimal in some
US regions [24], which suggests that reductions in disease in-
cidence could not be attributed to vaccination alone.
Although it was not a primary objective, there was no evi-
dence for a decrease in hospitalization for pneumonia in the
7vPCV era in the Alaskan Native population observational
study, which involved another setting with an unusually heavy
and early burden of respiratory illness [25]. Similarly, the only
statistically supported effect observed in the 11-valent pneu-
mococcal conjugate vaccine trial conducted in the Philippines
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Table 5. Unadjusted Hazard Ratios (HRs) and Adjusted Hazard Rate Ratios (HRRs) for Acute Lower Respiratory Tract Infection (ALRI),
Pneumonia, and Gastroenteritis in Northern Territory Indigenous Children 5–23 Months of Age, by Vaccine Type and Dose Comparison
Vaccine,
dose comparison
ALRI
(n p 2174 episodes)
Pneumoniaa
(n p 999 episodes)
Radiologically confirmed
pneumoniab
(n p 259 episodes)
Acute gastroenteritis
(n p 1725 episodes)
Unadjusted HRc Adjusted HRRd Unadjusted HRc Adjusted HRRd Unadjusted HRc Adjusted HRRd Unadjusted HRc Adjusted HRRd
7vPCV
1 vs 0 1.21 (1.04–1.41) 1.15 (0.98–1.34) 1.23 (0.98–1.55) 1.15 (0.91–1.46) 0.93 (0.57–1.52) 0.85 (0.53–1.38) 1.05 (0.87–1.26) 1.00 (0.83–1.20)
2 vs 0 1.32 (1.16–1.49) 1.25 (1.10–1.43) 1.42 (1.18–1.73) 1.33 (1.09–1.61) 1.14 (0.80–1.62) 1.02 (0.71–1.49) 1.09 (0.94–1.27) 1.02 (0.88–1.19)
3 vs 0 1.17 (1.04–1.32) 1.15 (1.02–1.30) 1.08 (0.90–1.28) 1.06 (0.89–1.27) 1.07 (0.78–1.46) 1.02 (0.74–1.41) 1.13 (0.99–1.28) 1.10 (0.97–1.26)
23vPPV
1 vs 0 1.39 (1.12–1.72) 1.39 (1.12–1.71) 1.55 (1.16–2.06) 1.55 (1.17–2.05) 2.89 (0.98–8.46) 2.31 (0.79–6.80) 0.97 (0.77–1.22) 1.00 (0.79–1.25)
1 (!3 7vPCV) vs 0 1.80 (1.31–2.47) 1.81 (1.32–2.48) 1.85 (1.24–2.78) 1.85 (1.23–2.77) 2.88 (0.41–20.2) 2.25 (0.43–11.8) 1.08 (0.74–1.57) 1.13 (0.78–1.65)
1 (3 7vPCV) vs 0 1.26 (1.00–1.60) 1.25 (0.99–1.59) 1.43 (1.04–1.98) 1.43 (1.03–1.98) 2.89 (0.84–9.94) 2.35 (0.61–9.06) 0.94 (0.73–1.21) 0.96 (0.75–1.23)
NOTE. 7vPCV, 7-valent pneumococcal conjugate vaccine; 23vPPV, 23-valent pneumococcal polysaccharide vaccine.
a Excludes specified viral pneumonias, influenza, bronchitis, and bronchiolitis.
b World Health Organization–defined end point consolidation on chest radiograph obtained within 3 days of hospital admission.
c Adjusted for multiple episodes within a child.
d Adjusted for sex, region, prior hospital admission for ALRI, prior hospital admission for non-ALRI cause, and multiple episodes within a child.
Table 6. Unadjusted and Adjusted Hazard Ratios (HRs) for Acute Lower Respiratory
Tract Infection (ALRI) by Vaccine, Vaccination Status, and Time Since Vaccination among
Northern Territory Indigenous Infants 5–23 Months of Age
Vaccine, time since vaccination
Unadjusted HR
(95% Confidence Interval)a
Adjusted HR
(95% Confidence Interval)b
7vPCV
!1 month after dose 1 1.21 (0.89–1.65) 1.15 (0.84–1.56)
1 month after dose 1 1.16 (0.98–1.38) 1.10 (0.93–1.32)
!1 month after dose 2 1.26 (1.00–1.58) 1.19 (0.95–1.50)
1 month after dose 2 1.35 (1.17–1.55) 1.28 (1.11–1.47)
!1 month after dose 3 1.37 (1.11–1.68) 1.32 (1.07–1.62)
1 month after dose 3 1.14 (1.01–1.29) 1.12 (0.98–1.27)
23vPPV
!1 month after vaccine 0.73 (0.49–1.08) 0.72 (0.49–1.08)
1 month after vaccine 1.49 (1.19–1.88) 1.49 (1.19–1.86)
NOTE. 7vPCV, 7-valent pneumococcal conjugate vaccine; 23vPPV, 23-valent pneumococcal polysac-
charide vaccine.
a Adjusted for multiple episodes within a child.
b Adjusted for sex, region, prior hospital admission for ALRI, prior hospital admission for non-ALRI cause,
and multiple episodes within a child.
was for WHO-defined, chest radiograph–confirmed pneumo-
nia in vaccinated infants aged 3–11 months (vaccine efficacy,
34.0%; 95% CI, 4.8%–54.3%), with no impact on other res-
piratory end points or among older children [26]. There were
increases in respiratory events after vaccination (within 28–60
days) in the clinical trials of the 7-, 9- and 11-valent pneu-
mococcal conjugate vaccines in the United States, The Gam-
bia [27], South Africa [28], and the Philippines [26]. Ongoing
monitoring of these respiratory events has been identified as
an important inclusion in post-licensure adverse event sur-
veillance [29, 30].
The potential mechanisms behind increases in respiratory
events after pneumococcal conjugate vaccination and after
23vPPV vaccination in the NT are speculative, particularly
when considering the clear benefit of the 7vPCV on vaccine-
type invasive pneumococcal disease (IPD) in these children
[31]. One explanation may be rapid replacement with non-
vaccine serotypes or other respiratory pathogens that have a
higher relative propensity to cause mucosal disease. Site-specif-
ic disease potential associated with carriage of pneumococcal
serotypes has been reported in several studies [32–35]. In our
population, intense and early nasopharyngeal colonization with
respiratory pathogens occurs as early as 21 days of age [22].
Cross-sectional carriage surveys from before and after the in-
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troduction of 7vPCV involving children 6–30 months of age
have shown that, although the 7vPCV serotypes have disap-
peared, overall rates of carriage of non–vaccine-type pneu-
mococci, H. influenzae and Moraxella catarrhalis remain un-
changed [36]. Rapid replacement with mucogenic agents in the
NT may increase ALRI in parallel with reductions in vaccine-
type IPD and carriage. It is not known why the risk might be
greater among children vaccinated with the 23vPPV who have
not had a full primary course of 7vPCV, although recent data
from Fiji indicate that the boosting effect of 23vPPV was more
pronounced in children who had received 1 dose of 7vPCV
than it was in those who had received 2 or 3 doses [37]. Al-
though IPD case numbers are too small to provide supporting
evidence, a second theoretical reason for our findings is the
occurrence of immune hyporesponsiveness. This phenomenon
has been observed after the use of meningococcal polysaccha-
ride vaccine [38] and in the Fiji study. Attributing our findings
to hyporesponsiveness is difficult, particularly given that IPD
and carriage of 7vPCV serotypes have all but been eliminated.
Our study lacked information on some potentially important
confounders, including household size, breast feeding (al-
though only 45% of Indigenous children aged 6–12 months
are currently breast fed [39]), birth weight, socioeconomic status
of the parents, and exposure to tobacco smoke. Although residual
confounding is possible, we have attempted to account for these
variables by incorporating potential (albeit nonspecific) indica-
tors of these factors in Indigenous children, such as anemia,
malnutrition, prior hospitalizations for any cause, and prior hos-
pitalizations for ALRI.
The use of discharge diagnosis codes alone as end points
may be unreliable [40–42]. Direct clinical information would
provide more certainty and add valuable disease severity data.
Restricting the analysis to chest radiograph–confirmed pneu-
monia cases in this analysis was not helpful because of small
case numbers. Furthermore, this study, being a secondary anal-
ysis of previously collected data, does not include risk infor-
mation beyond 2 years of age, which is an important area for
further research.
It is undisputed that the NT pneumococcal immunization
program reduces 7vPCV vaccine-type IPD. However, our data
suggest that reevaluation of the use of the 23vPPV booster at
18 months should be a matter of priority. The long-term se-
quelae of ALRI in these infants, particularly those who expe-
rience repeat infection, and the high prevalence of non–cystic
fibrosis bronchiectasis associated with repeat ALRI, are major
public health issues [43]. Additional work to confirm our find-
ings with prospectively collected data with validated end points
and stronger control of potential confounders is required.
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